Literature DB >> 32118251

SynergyFinder: a web application for analyzing drug combination dose-response matrix data.

Aleksandr Ianevski, Liye He, Tero Aittokallio, Jing Tang.   

Abstract

Entities:  

Year:  2020        PMID： 32118251      PMCID： PMC7178425          DOI： 10.1093/bioinformatics/btaa102

Source DB:  PubMed          Journal:  Bioinformatics        ISSN： 1367-4803            Impact factor:   6.937


× No keyword cloud information.
Bioinformatics (2017), 33, 2017, 2413–2415, doi: 10.1093/bioinformatics/btx162 The following funding source was inadvertently omitted from the above article: European Research Council (ERC) starting grant DrugComb (Informatics approaches for the rationale selection of personaliszed cancer drug combinations) [No. 716063] This has now been added.
  10 in total

1.  Statins repress hedgehog signaling in medulloblastoma with no bone toxicities.

Authors:  Qianhai Fan; Tingting Gong; Chaonan Zheng; Jessica M Y Ng; Jianquan Chen; Cynthia Myers; Harvey Hensley; Tom Curran; Zeng-Jie Yang
Journal:  Oncogene       Date:  2021-03-01       Impact factor: 9.867

2.  Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma.

Authors:  Ashuvinee Elangovan; Jagmohan Hooda; Laura Savariau; Susrutha Puthanmadhomnarayanan; Megan E Yates; Jian Chen; Daniel D Brown; Priscilla F McAuliffe; Steffi Oesterreich; Jennifer M Atkinson; Adrian V Lee
Journal:  Mol Cancer Res       Date:  2022-09-02       Impact factor: 6.333

3.  Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.

Authors:  Justyna M Przystal; Chiara Cianciolo Cosentino; Sridevi Yadavilli; Jie Zhang; Sandra Laternser; Erin R Bonner; Rachna Prasad; Adam A Dawood; Nina Lobeto; Wai Chin Chong; Matt C Biery; Carrie Myers; James M Olson; Eshini Panditharatna; Bettina Kritzer; Sulayman Mourabit; Nicholas A Vitanza; Mariella G Filbin; Geoffry N de Iuliis; Matthew D Dun; Carl Koschmann; Jason E Cain; Michael A Grotzer; Sebastian M Waszak; Sabine Mueller; Javad Nazarian
Journal:  Neuro Oncol       Date:  2022-09-01       Impact factor: 13.029

4.  JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis.

Authors:  Juhee Son; Shimeng Huang; Qiru Zeng; Traci L Bricker; James Brett Case; Jinzhu Zhou; Ruochen Zang; Zhuoming Liu; Xinjian Chang; Tamarand L Darling; Jian Xu; Houda H Harastani; Lu Chen; Maria Florencia Gomez Castro; Yongxiang Zhao; Hinissan P Kohio; Gaopeng Hou; Baochao Fan; Beibei Niu; Rongli Guo; Paul W Rothlauf; Adam L Bailey; Xin Wang; Pei-Yong Shi; Elisabeth D Martinez; Steven L Brody; Sean P J Whelan; Michael S Diamond; Adrianus C M Boon; Bin Li; Siyuan Ding
Journal:  mBio       Date:  2022-01-18       Impact factor: 7.786

5.  Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment.

Authors:  John C Dawson; Alison Munro; Kenneth Macleod; Morwenna Muir; Paul Timpson; Robert J Williams; Margaret Frame; Valerie G Brunton; Neil O Carragher
Journal:  Mol Oncol       Date:  2021-12-18       Impact factor: 6.603

6.  Metabolic drug survey highlights cancer cell dependencies and vulnerabilities.

Authors:  Tea Pemovska; Johannes W Bigenzahn; Ismet Srndic; Alexander Lercher; Andreas Bergthaler; Adrián César-Razquin; Felix Kartnig; Christoph Kornauth; Peter Valent; Philipp B Staber; Giulio Superti-Furga
Journal:  Nat Commun       Date:  2021-12-14       Impact factor: 14.919

7.  The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters.

Authors:  Andrea Savarino; Marina Lusic; Iart Luca Shytaj; Mohamed Fares; Lara Gallucci; Bojana Lucic; Mahmoud M Tolba; Liv Zimmermann; Julia M Adler; Na Xing; Judith Bushe; Achim D Gruber; Ina Ambiel; Ahmed Taha Ayoub; Mirko Cortese; Christopher J Neufeldt; Bettina Stolp; Mohamed Hossam Sobhy; Moustafa Fathy; Min Zhao; Vibor Laketa; Ricardo Sobhie Diaz; Richard E Sutton; Petr Chlanda; Steeve Boulant; Ralf Bartenschlager; Megan L Stanifer; Oliver T Fackler; Jakob Trimpert
Journal:  mBio       Date:  2022-03-01       Impact factor: 7.786

8.  Anti-cancer properties of cannflavin A and potential synergistic effects with gemcitabine, cisplatin, and cannabinoids in bladder cancer.

Authors:  Andrea M Tomko; Erin G Whynot; Denis J Dupré
Journal:  J Cannabis Res       Date:  2022-07-22

9.  Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells.

Authors:  Marielle Huot; Maxime Caron; Chantal Richer; Rahinatou Djibo; Rafael Najmanovich; Pascal St-Onge; Daniel Sinnett; Noël J M Raynal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-31       Impact factor: 3.333

10.  Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis

Authors:  Sheila Bohler; Sehar Afreen; Juncal Fernandez-Orth; Eva-Maria Demmerath; Christian Molnar; Ying Wu; Julia Miriam Weiss; Venugopal Rao Mittapalli; Lukas Konstantinidis; Hagen Schmal; Mirjam Kunze; Miriam Erlacher
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.